Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights.
Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Atara Biotherapeutics Company is mentioned.
We assess its relevance and importance to carry out an overall sentiment valuation of Atara Biotherapeutics, Inc. (ATRA).
You can view the trend designation for each individual article below.
We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Atara Biotherapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend:Neutral
March 28, 2024 (06:22) / "Stocknews.com" (by Defense World Staff)
Atara Biotherapeutics ( NASDAQ:ATRA - Get Free Report ) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday. NASDAQ:ATRA opened at $0.70 on Thursday.
In Article Trend:Somewhat-Bullish
March 19, 2024 (08:06) / "Stocknews.com" (by Defense World Staff)
StockNews.com downgraded shares of Atara Biotherapeutics ( NASDAQ:ATRA - Free Report ) from a hold rating to a sell rating in a report published on Monday. NASDAQ:ATRA opened at $0.60 on Monday. The stock's fifty day moving average is $0.74 and its two-hundred day moving average is $0.94.
Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initiated clinical trial of Phase 1 P-CD19CD20-ALLO1, the Company's first allogeneic dual CAR-T program
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 9.09% and 34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend:Neutral
February 23, 2024 (13:10) / "Canada Newswire" (by Pierre Fabre)
CASTRES, France, Feb. 23, 2024 /CNW/ -- Rare Disease Day® will be held on February 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative prescription drugs to children, as young patients require appropriate treatments.
In Article Trend:Somewhat-Bullish
February 5, 2024 (13:04) / "Benzinga" (by Avi Kapoor)
Shares of 4D Molecular Therapeutics, Inc. FDMT rose sharply in today's pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and,
moreover, are not trading signals.
When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market
as a result of using the information contained on the site.
This website uses cookies to ensure you get the best experience on our website